Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

Abstract The aim of this study was to explore the male predominance in esophageal and gastric adenocarcinoma by evaluating the preventive potential of androgen deprivation therapy (ADT). This matched cohort study was based on a national Swedish database of prostate cancer patients in 2006–2013. Pros...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard Shore, Jingru Yu, Weimin Ye, Jesper Lagergren, Martin Rutegård, Olof Akre, Pär Stattin, Mats Lindblad
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5613e691bb464c97b6d04ced585359f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5613e691bb464c97b6d04ced585359f4
record_format	dspace
spelling	oai:doaj.org-article:5613e691bb464c97b6d04ced585359f42021-12-02T14:33:57ZRisk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer10.1038/s41598-021-92347-02045-2322https://doaj.org/article/5613e691bb464c97b6d04ced585359f42021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92347-0https://doaj.org/toc/2045-2322Abstract The aim of this study was to explore the male predominance in esophageal and gastric adenocarcinoma by evaluating the preventive potential of androgen deprivation therapy (ADT). This matched cohort study was based on a national Swedish database of prostate cancer patients in 2006–2013. Prostate cancer patients receiving ADT were the exposed group. Prostate cancer-free men from the general population were randomly selected and matched to the index case by birth year and county of residence, forming the unexposed control group. The participants were followed until a diagnosis of esophageal or gastric cancer, death, emigration, or end of the study period. The risk of esophageal adenocarcinoma, cardia gastric adenocarcinoma, non-cardia gastric adenocarcinoma, and esophageal squamous-cell carcinoma among ADT-exposed compared to unexposed was calculated by multivariable Cox proportional hazard regression. The hazard ratios (HRs) and 95% confidence intervals (CIs) were adjusted for confounders. There was a risk reduction of non-cardia gastric adenocarcinoma among ADT-users compared to non-users (HR 0.49 [95% CI 0.24–0.98]). No such decreased risk was found for esophageal adenocarcinoma (HR 1.17 [95% CI 0.60–2.32]), cardia gastric adenocarcinoma (HR 0.99 [95% CI 0.40–2.46]), or esophageal squamous cell carcinoma (HR 0.99 [95% CI 0.31–3.13]). This study indicates that androgen deprivation therapy decreases the risk of non-cardia gastric adenocarcinoma, while no decreased risk was found for esophageal adenocarcinoma, cardia gastric adenocarcinoma, or esophageal squamous-cell carcinoma.Richard ShoreJingru YuWeimin YeJesper LagergrenMartin RutegårdOlof AkrePär StattinMats LindbladNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Richard Shore Jingru Yu Weimin Ye Jesper Lagergren Martin Rutegård Olof Akre Pär Stattin Mats Lindblad Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
description	Abstract The aim of this study was to explore the male predominance in esophageal and gastric adenocarcinoma by evaluating the preventive potential of androgen deprivation therapy (ADT). This matched cohort study was based on a national Swedish database of prostate cancer patients in 2006–2013. Prostate cancer patients receiving ADT were the exposed group. Prostate cancer-free men from the general population were randomly selected and matched to the index case by birth year and county of residence, forming the unexposed control group. The participants were followed until a diagnosis of esophageal or gastric cancer, death, emigration, or end of the study period. The risk of esophageal adenocarcinoma, cardia gastric adenocarcinoma, non-cardia gastric adenocarcinoma, and esophageal squamous-cell carcinoma among ADT-exposed compared to unexposed was calculated by multivariable Cox proportional hazard regression. The hazard ratios (HRs) and 95% confidence intervals (CIs) were adjusted for confounders. There was a risk reduction of non-cardia gastric adenocarcinoma among ADT-users compared to non-users (HR 0.49 [95% CI 0.24–0.98]). No such decreased risk was found for esophageal adenocarcinoma (HR 1.17 [95% CI 0.60–2.32]), cardia gastric adenocarcinoma (HR 0.99 [95% CI 0.40–2.46]), or esophageal squamous cell carcinoma (HR 0.99 [95% CI 0.31–3.13]). This study indicates that androgen deprivation therapy decreases the risk of non-cardia gastric adenocarcinoma, while no decreased risk was found for esophageal adenocarcinoma, cardia gastric adenocarcinoma, or esophageal squamous-cell carcinoma.
format	article
author	Richard Shore Jingru Yu Weimin Ye Jesper Lagergren Martin Rutegård Olof Akre Pär Stattin Mats Lindblad
author_facet	Richard Shore Jingru Yu Weimin Ye Jesper Lagergren Martin Rutegård Olof Akre Pär Stattin Mats Lindblad
author_sort	Richard Shore
title	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
title_short	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
title_full	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
title_fullStr	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
title_full_unstemmed	Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
title_sort	risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5613e691bb464c97b6d04ced585359f4
work_keys_str_mv	AT richardshore riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT jingruyu riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT weiminye riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT jesperlagergren riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT martinrutegard riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT olofakre riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT parstattin riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer AT matslindblad riskofesophagealandgastricadenocarcinomainmenreceivingandrogendeprivationtherapyforprostatecancer
_version_	1718391129478529024

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

Ejemplares similares